- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02633176
Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
Phase Ⅲ Randomized Trial of Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel Induction Chemotherapy Followed by Concurrent Chemoradiation in Previously Untreated Patients Metastatic Nasopharyngeal Carcinoma
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Očekávaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Fujian
-
Fuzhou, Fujian, Čína, 350014
- Nábor
- Fujian Provincial Cancer Hospital
-
Kontakt:
- Cheng Huang, MD
- E-mail: cheng671@sina.com
-
Vrchní vyšetřovatel:
- Cheng Huang, MD
-
-
Guangdong
-
Guangzhou, Guangdong, Čína, 510060
- Nábor
- Sun Yat-sen University Cancer Center
-
Kontakt:
- Zhao Wang, MD
- Telefonní číslo: +86-20-87343694
- E-mail: wangzhao@sysucc.org.cn
-
Dílčí vyšetřovatel:
- He Huang, MD
-
Guangzhou, Guangdong, Čína, 510080
- Nábor
- The First Affiliated Hospital of Sun Yat-sen University
-
Kontakt:
- Mengping Zhang, MD
- Telefonní číslo: +86-20-87755766-8576
- E-mail: zhangmp1989@163.com
-
Vrchní vyšetřovatel:
- Sheng Ye, MD
-
-
Guangxi
-
Nanning, Guangxi, Čína, 530021
- Nábor
- Guangxi Cancer Hospital
-
Vrchní vyšetřovatel:
- Xiaohua Hu, MD
-
Kontakt:
- Chaoyong Liang, MD
- E-mail: lmlm1995@qq.com
-
-
Hubei
-
Wuhan, Hubei, Čína, 430022
- Nábor
- Union Hospital,Tongji Medical College of Huazhong University of Science & Technology
-
Kontakt:
- Gang Wu, MD
- E-mail: xhzlwg@163.com
-
Vrchní vyšetřovatel:
- Gang Wu, MD
-
Wuhan, Hubei, Čína, 430030
- Nábor
- Tongji Hospital,Tongji Medical College of Huazhong University of Science & Technology
-
Kontakt:
- Shiying Yu, MD
- E-mail: syyu@tjh.tjmu.edu.cn
-
Vrchní vyšetřovatel:
- Shiying Yu, MD
-
-
Jiangsu
-
Nanjing, Jiangsu, Čína, 210000
- Nábor
- Jiangsu Cancer Hospital
-
Kontakt:
- Jifeng Feng, MD
- E-mail: fjif@vip.sina.com
-
Vrchní vyšetřovatel:
- Jifeng Feng, MD
-
-
Shanghai
-
Shanghai, Shanghai, Čína, 200032
- Nábor
- Fudan University Shanghai Cancer Center
-
Kontakt:
- Xichun Hu, MD
- E-mail: xchu2009@hotmail.com
-
Vrchní vyšetřovatel:
- Xichun Hu, MD
-
-
Sichuan
-
Chengdu, Sichuan, Čína, 610047
- Nábor
- Sichuan Cancer Hospital
-
Kontakt:
- Jinyi Lang, MD
- E-mail: langjy610@163.com
-
Vrchní vyšetřovatel:
- Jinyi Lang, MD
-
-
Zhejiang
-
Hangzhou, Zhejiang, Čína, 310022
- Nábor
- Zhejiang Cancer Hospital
-
Kontakt:
- Yuan Zhu, MD
- E-mail: zhuyuan63@hotmail.com
-
Vrchní vyšetřovatel:
- Yuan Zhu, MD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Histologically or cytologically confirmed nasopharyngeal carcinoma
- Untreated metastatic nasopharyngeal carcinoma (stage ⅣC according to the 7th American Joint Committee on Cancer staging system and stage ⅣB according to the Chinese 2008 staging system for nasopharyngeal carcinoma)
- Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 6 months
- Absolute neutrophil count (ANC) >=1.5×10^9/L
- Platelets >= 80×10^9/L
- Hemoglobin >= 90 g/l
- Bilirubin <= 1.5 × upper limit of normal (ULN)
- Aminopherases ( alanine transaminase and aspartate aminotransferase) <= 2.5 × ULN (without liver metastasis) or <= 5.0 × ULN (with liver metastasis)
- Creatinine <=ULN
- International normalized ratio (INR) of prothrombin time (PT) <= 1.5 × ULN
- The pregnancy tests of women of childbearing potential should be negative before treatment
- Women of childbearing potential and sexually active males must adopt efficient contraception methods while on treatment and for six months after the completion of the treatment
- Patients should understand and are willing to participate in the study. Inform consent form is supposed to obtained before treatment
Exclusion Criteria:
- Prior radiotherapy of target lesions
- Prior systemic chemotherapy and/or targeted therapy
- Brain metastasis
- Concurrent other malignancies
- Severe or active infectious disease requiring systemic antibiotics or antiviral, antifungal treatment
- Active tuberculosis
- Severe cardiovascular disease, including uncontrolled hypertension, unstable angina, myocardial infarction in the past 6 months, congestive heart failure with cardiac function grade Ⅲ to Ⅳ based on New York Heart Association cardiac functional grading, serious arrhythmia, or pericardial effusion
- Co-existing mental disease that would preclude full compliance with the study
- Females are pregnant or breast feeding
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Aktivní komparátor: cisplatin and docetaxel
Induction chemotherapy: Patients receive cisplatin and docetaxel intravenously on day 1 repeated every 3 weeks for 6 cycles. Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cisplatin 30mg/m^2 intravenously every week. Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression. |
75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30
mg/m^2 intravenously every week concurrent with radiotherapy.
75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
Ostatní jména:
1000mg/m^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
Ostatní jména:
60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
|
Experimentální: cetuximab, cisplatin, and docetaxel
Induction chemotherapy: Patients receive cetuximab 400mg/m^2 intravenously over at least 120 minutes on day 1 followed by 250 mg/m^2 intravenously over at least 60 minutes every week. Cisplatin and docetaxel will be administered intravenously on day 2 repeated every 3 weeks for 6 cycles. Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cetuximab 250mg/m^2 intravenously followed by cisplatin 30mg/m^2 intravenously every week. Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression. |
75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30
mg/m^2 intravenously every week concurrent with radiotherapy.
75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
Ostatní jména:
1000mg/m^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
Ostatní jména:
60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
400 mg/m^2 intravenously on day 1,then 250 mg/m^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250
mg/m^2 intravenously every week concurrent with radiotherapy.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Progression-free survival
Časové okno: From date of randomization until the date of first documented progression, date of death from any cause, or date of last assessment, whichever came first, assessed up to 5 years
|
Progression-free survival was defined as the time from date of randomization until the date of first documented progression, date of death from any cause, or date of last assessment, whichever came first.
All eligible and treated patients were included in the analysis.
|
From date of randomization until the date of first documented progression, date of death from any cause, or date of last assessment, whichever came first, assessed up to 5 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Event-free Survival
Časové okno: From date of randomization until the date of first documented progression, date of death from any cause, date of introduction of a new treatment, or date of last assessment, whichever came first, assessed up to 5 years.
|
Event-free survival was defined as the time from date of randomization until the date of first documented progression, date of death from any cause, date of introduction of a new treatment without evidence of progression or relapse, or date of last assessment, whichever came first.
All eligible and treated patients were included in the analysis.
|
From date of randomization until the date of first documented progression, date of death from any cause, date of introduction of a new treatment, or date of last assessment, whichever came first, assessed up to 5 years.
|
Disease-free Survival
Časové okno: From date of attainment a complete response until the date of first documented relapse, date of death from NPC or treatment-related toxicities, or date of last assessment, whichever came first, assessed up to 5 years.
|
Disease-free survival was defined as the time from date of attainment a complete response until the date of first documented relapse, date of death from NPC or treatment-related toxicities, or date of last assessment, whichever came first.
All eligible and treated patients were included in the analysis.
|
From date of attainment a complete response until the date of first documented relapse, date of death from NPC or treatment-related toxicities, or date of last assessment, whichever came first, assessed up to 5 years.
|
Overall Survival
Časové okno: From date of randomization until the date of death from any cause, or date of last assessment, whichever came first, assessed up to 5 years.
|
Overall survival was defined as the time from randomization until the date of death from any cause, or date of last assessment, whichever came first.
All eligible and treated patients were included in the analysis.
|
From date of randomization until the date of death from any cause, or date of last assessment, whichever came first, assessed up to 5 years.
|
Overall response rate
Časové okno: every 6 weeks, up to 5 years.
|
Tumor response was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Overall response rate= complete response + partial response.
Tumor measurements were performed using physical examination, computer tomography (CT) or Positron Emission Tomography-Computer Tomography (PET-CT) scans and Magnetic Resonance Imaging (MRI) scans, which were consist with baseline measurements methods.
|
every 6 weeks, up to 5 years.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Tongyu Lin, MD, Sun Yat-sen University
- Vrchní vyšetřovatel: Taixiang Lu, MD, Sun Yat-sen University
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary podle histologického typu
- Novotvary
- Novotvary podle místa
- Novotvary, žlázové a epiteliální
- Novotvary hltanu
- Otorinolaryngologické novotvary
- Novotvary hlavy a krku
- Nemoci nosohltanu
- Faryngeální onemocnění
- Stomatognátní onemocnění
- Otorinolaryngologická onemocnění
- Novotvary nosohltanu
- Karcinom
- Karcinom nosohltanu
- Molekulární mechanismy farmakologického působení
- Antimetabolity, Antineoplastika
- Antimetabolity
- Antineoplastická činidla
- Tubulinové modulátory
- Antimitotické látky
- Modulátory mitózy
- Antineoplastická činidla, Imunologická
- Docetaxel
- Kapecitabin
- Cetuximab
Další identifikační čísla studie
- CSWOG0103
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .